HUP0000587A1 - Takrolimuszt (FK506) tartalmazó gyógyszerkészítmény - Google Patents

Takrolimuszt (FK506) tartalmazó gyógyszerkészítmény

Info

Publication number
HUP0000587A1
HUP0000587A1 HU0000587A HUP0000587A HUP0000587A1 HU P0000587 A1 HUP0000587 A1 HU P0000587A1 HU 0000587 A HU0000587 A HU 0000587A HU P0000587 A HUP0000587 A HU P0000587A HU P0000587 A1 HUP0000587 A1 HU P0000587A1
Authority
HU
Hungary
Prior art keywords
pharmaceutical composition
composition containing
containing tacrolimus
tacrolimus
surfactant
Prior art date
Application number
HU0000587A
Other languages
English (en)
Inventor
Takehisa Hata
Takeo Hirose
Sumihisa Kimura
Fumio Shimojo
Yuji Tokunaga
Satoshi Ueda
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Publication of HUP0000587A1 publication Critical patent/HUP0000587A1/hu
Publication of HUP0000587A3 publication Critical patent/HUP0000587A3/hu
Publication of HU228680B1 publication Critical patent/HU228680B1/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A találmány tárgya vízőldhatatlan gyógyászati hatóanyagőt, pl.:takőliműszt (FK 506) felületaktív anyagő(ka)t és szilárd hőrdőzó(ka)ttartalmazó gyógyszerkészítmény, mely javítőtt őldhatósági és őrálisfelszívódási tűlajdőnságőkkal rendelkezik. ŕ
HU0000587A 1996-12-06 1997-12-05 Pharmaceutical composition containing tacrolimus (fk506) HU228680B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP32661896 1996-12-06
PCT/JP1997/004452 WO1998024418A1 (fr) 1996-12-06 1997-12-05 Compositions medicinales

Publications (3)

Publication Number Publication Date
HUP0000587A1 true HUP0000587A1 (hu) 2000-09-28
HUP0000587A3 HUP0000587A3 (en) 2001-12-28
HU228680B1 HU228680B1 (en) 2013-05-28

Family

ID=18189823

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000587A HU228680B1 (en) 1996-12-06 1997-12-05 Pharmaceutical composition containing tacrolimus (fk506)

Country Status (17)

Country Link
US (1) US6346537B1 (hu)
EP (1) EP0943327B1 (hu)
JP (1) JP4284706B2 (hu)
KR (1) KR20000057242A (hu)
CN (1) CN1149979C (hu)
AR (1) AR008927A1 (hu)
AT (1) ATE367150T1 (hu)
AU (1) AU726451B2 (hu)
BR (1) BR9713866A (hu)
CA (1) CA2274485C (hu)
DE (1) DE69737936T2 (hu)
ES (1) ES2286835T3 (hu)
HU (1) HU228680B1 (hu)
RU (1) RU2197226C2 (hu)
TW (1) TW426516B (hu)
WO (1) WO1998024418A1 (hu)
ZA (1) ZA9710927B (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1064942B9 (en) 1998-03-26 2011-03-02 Fujisawa Pharmaceutical Co., Ltd. Sustained release preparation of a macrolide
FR2781373B1 (fr) * 1998-07-07 2001-09-21 Pf Medicament Formulations thixotropes pour le remplissage de gelules
CA2364257A1 (en) * 1999-03-11 2000-09-14 Fujisawa Pharmaceutical Co., Ltd. Liposome preparations
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition
ATE395044T1 (de) 2002-02-01 2008-05-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
EP1517682B1 (en) * 2002-06-28 2006-11-02 Speedel Pharma AG Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant
KR100486016B1 (ko) * 2003-07-09 2005-04-29 주식회사종근당 타크로리무스의 속용성 고체분산체 및 이의 제조방법
ATE540671T1 (de) 2003-08-04 2012-01-15 Bend Res Inc Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
ATE531368T1 (de) * 2003-08-29 2011-11-15 Veloxis Pharmaceuticals As Tacrolimus enthaltende zusammensetzungen mit modifizierter freisetzung
AU2004267909B2 (en) 2003-08-29 2008-12-18 Veloxis Pharmaceuticals, Inc. Modified release compositions comprising tacrolimus
KR100866728B1 (ko) * 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
US7652364B2 (en) * 2005-12-21 2010-01-26 Teradata Us, Inc. Crossing conductive traces in a PCB
GB0602632D0 (en) * 2006-02-08 2006-03-22 Pliva Istrazivacki Inst D O O Preparation Of A Solid Dosage From Comprising Tacrolimus And/Or Sirolimus
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
US9044391B2 (en) * 2007-01-10 2015-06-02 Board Of Regents, The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
KR100868295B1 (ko) * 2007-02-15 2008-11-11 풍림무약주식회사 레플루노미드를 함유하는 고체분산체 및 이의 제조방법
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
EP2167033B1 (en) 2007-05-30 2017-04-19 Veloxis Pharmaceuticals A/S Once daily oral dosage form comprising tacrolimus
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
US8222272B2 (en) 2008-04-11 2012-07-17 Roxane Laboratories, Inc. Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus)
CN101580535B (zh) * 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
CA2729948C (en) * 2008-07-08 2021-11-23 Lifecycle Pharma A/S Tacrolimus for improved treatment of transplant patients
CN102149715A (zh) * 2008-09-17 2011-08-10 Cj第一制糖株式会社 肝适能的稳定化固态分散物及其制备方法
DK2575769T3 (en) 2010-02-17 2016-09-26 Veloxis Pharmaceuticals As stabilized tacrolismussammensætning
WO2011116034A1 (en) * 2010-03-17 2011-09-22 Lutran Industries, Inc. Human medicinal treatment and product typically based on salt of peroxymonosulfuric acid, and associated product fabrication
US10383894B2 (en) * 2010-03-17 2019-08-20 Lutran Industries, Inc. Human medicinal treatment using salt of peroxymonosulfuric acid
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
CN105663092A (zh) * 2016-03-03 2016-06-15 海南华益泰康药业有限公司 一种含有他克莫司固体分散体的缓释胶囊及其制备方法
US11154522B2 (en) 2016-05-26 2021-10-26 Dermala Inc. Compositions and methods for treating acne vulgaris

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
ZA905202B (en) 1989-07-05 1991-04-24 Fujisawa Pharmaceutical Co Aqueous liquid composition for external use
US5215995A (en) 1989-10-16 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Hair revitalizing agent
KR0177158B1 (ko) * 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
CA2054983A1 (en) 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
US5817333A (en) 1991-10-31 1998-10-06 Fujisawa Pharmaceutical Co., Ltd. Liposome preparation containing a tricyclic compound
EP0669127B1 (en) 1992-11-18 1999-08-11 Fujisawa Pharmaceutical Co., Ltd. Prolonged-action pharmaceutical preparation
JPH07291854A (ja) * 1994-04-26 1995-11-07 Tanabe Seiyaku Co Ltd 溶解性の改善された医薬品製剤
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees

Also Published As

Publication number Publication date
AR008927A1 (es) 2000-02-23
EP0943327B1 (en) 2007-07-18
DE69737936D1 (de) 2007-08-30
CN1245424A (zh) 2000-02-23
ES2286835T3 (es) 2007-12-01
HU228680B1 (en) 2013-05-28
ATE367150T1 (de) 2007-08-15
EP0943327A1 (en) 1999-09-22
HUP0000587A3 (en) 2001-12-28
BR9713866A (pt) 2000-03-14
DE69737936T2 (de) 2007-12-06
JP4284706B2 (ja) 2009-06-24
CN1149979C (zh) 2004-05-19
CA2274485C (en) 2008-02-05
AU5136998A (en) 1998-06-29
US6346537B1 (en) 2002-02-12
KR20000057242A (ko) 2000-09-15
EP0943327A4 (en) 2003-06-25
CA2274485A1 (en) 1998-06-11
RU2197226C2 (ru) 2003-01-27
TW426516B (en) 2001-03-21
WO1998024418A1 (fr) 1998-06-11
ZA9710927B (en) 1998-06-15
AU726451B2 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
HUP0000587A1 (hu) Takrolimuszt (FK506) tartalmazó gyógyszerkészítmény
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
LT2000064A (en) Flash-melt oral dosage formulation
CA2259148A1 (en) Solid oral dosage forms of valsartan
ATE336268T1 (de) Medizinische aerosolzubereitung
CA2416403A1 (en) A medicinal aerosol formulation
HUP0500509A2 (hu) Azonnali felszabadulást biztosító mikronizált gyógyászati és gyógytáp porok
HUP9903734A2 (hu) Szabályozott felszabadulású, orális gyógyszerkészítmények és eljárás ezek előállítására
HUP9900413A3 (en) Use of coralyne derivatives, new coralyne derivatives and use thereof, pharmaceutical compositions containing these new coralyne derivatives
BG105189A (en) Two-piece capsule for receiving pharmaceutical preparations for powder inhalers
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
CA2295035A1 (en) Pharmaceutical formulations containing voriconazole
ATE215359T2 (de) Aerosolformulierungen
HUP0103925A2 (hu) Formoterolt tartalmazó, stabilan tárolható hatóanyag-koncentrátum
PL337794A1 (en) Pharmaceutic agent for oral administration containing an active substance and cyclodextrin
DE60321774D1 (de) Aerosol-formulierungen von formoterol und mometason
HUP0103454A2 (hu) Entacapont vagy nitecapont és keresztkötésű cellulózszármazékot tartalmazó gyógyászati készítmény
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
MY127350A (en) Flash-melt oral dose formulations
HUP0104647A2 (hu) Hatóanyagként tilidin-mezilátot tartalmazó, szabályozott hatóanyag-leadású gyógyszerkészítmény
MY118569A (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
HUP0002346A1 (hu) Emlősök elmezavarainak kezelésére szolgáló gyógyszerkészítmény
WO2005009407A3 (en) Oral pharmaceutical formulations of olanzapine
GEP20043377B (en) Pharmaceutical Complex

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: ASTELLAS PHARMA INC., JP

Free format text: FORMER OWNER(S): FUJISAWA PHARMACEUTICAL CO., LTD., JP

MM4A Lapse of definitive patent protection due to non-payment of fees